News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website

 

Preclinical Data of Introgen`s INGN 241 Demonstrate Broad Anti-Cancer Activity In Multiple Tumor Types as Monotherapy and in Combination (PR Newswire)...INGN 241 can inhibit cell growth in multiple tumor types when used alone or in combination with established therapi......additional cancer indications including prostate, ovarian, bladder, brain, and breast cancer.......candidate, INGN 241 (Adenoviral-mda7), for the treatment of solid tumors, is in Phase I clinical development....- Jun 01 7:30 PM ET


IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://biz.yahoo.com/prnews/010601/daf010.html


(Everything below this line is from VirtualTrials.com!)

Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740